Clinical Trial

Etoricoxib in Patients With Parkinsonian Disease

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Neuroinflammation is considered one of the most important factors contributing critically to pathophysiology of PD . Recently, high mobility group box-1 (HMGB1) protein has been encoded as a potential inflammatory biomarker in PD. HMGB1 mediates immune response mostly through endothelial cells and macrophage activation via targeting two vital cell receptors; Toll-like receptor 4 (TLR4) and advanced glycation end products (RAGE).
Protocol Amendment History 1 change
critical Recruitment opened 2026-04-09
Trial Details
NCT Number NCT07370532
Lead Sponsor Ihab Elsayed Hassan
Conditions Parkinson Disease
Enrollment 60 participants
Start Date 2026-01-30
Primary Completion 2027-11-10 (estimated)
Study Completion 2027-11-20 (estimated)
Updated on ClinicalTrials.gov 2026-04-08